Document:

Document

[*]  Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

EXHIBIT 10.25.4
AMENDMENT 4 TO
LICENSE AND COLLABORATION AGREEMENT

This fourth Amendment (this “Amendment 4”) is effective as of the last date of signature (the “Amendment Effective Date”), and is entered into by and between MERCK SHARP & DOHME CORP., a corporation organized and existing under the laws of New Jersey (“Merck”), and BIOPROTECTION SYSTEMS CORPORATION, a corporation organized and existing under the laws of Delaware (“NewLink”) and a wholly owned subsidiary of NEWLINK GENETICS CORPORATION, a corporation organized and existing under the laws of Delaware (“NL”).

RECITALS:

WHEREAS, Merck and NewLink are parties to that certain License and Collaboration Agreement dated November 21, 2014, and further amended on December 5, 2017, May 10, 2018, and October 9, 2018 (the “Agreement”); and

WHEREAS, Merck and NewLink desire to further amend the Agreement as set forth herein.

NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, the receipt and sufficiency of which are hereby acknowledged, Merck and NewLink hereby agree as follows:

1.The Parties acknowledge and agree that the NewLink Canada License was amended and restated by NewLink and Public Health Canada on [*] with Merck’s prior written consent in accordance with Section 3.1.3 of the Agreement. Section 1.71 of the Agreement is hereby deleted in its entirety and replaced with the following:

1.71 “NewLink Canada License” means, collectively, (i) that certain Sole License Agreement for Recombinant Vesicular Stomatitis Virus Vaccines For Viral Hemorrhagic Fevers, between Her Majesty the Queen in Right of Canada (as represented by the Minister of Health, acting through the Public Health Agency of Canada (“Public Health Canada”)) and NewLink, [*] and (ii) that certain Material Transfer and License Agreement between Public Health Canada and NewLink dated as of [*], in each case, as the foregoing may be further amended in accordance with Section 3.1.3.

2.Section 3.1.4 of the Agreement is hereby deleted in its entirety and replaced with the following:

3.1.4  NewLink Canada License. The Parties acknowledge and agree that each Party has [*] to [*] and that neither Party has [*]. NewLink shall not amend, restate, amend and restate, terminate in whole or in part, or otherwise modify the NewLink Canada License without the prior written consent of Merck, not to be unreasonably withheld. Notwithstanding anything to the contrary herein, all licenses or other grants granted by NewLink to Merck hereunder with respect to any NewLink Know-How or NewLink Patent Rights that are owned by Public Health Canada and licensed to NewLink under the NewLink Canada License (the “Canada IP”) shall at all times be subject to the terms and conditions of the NewLink Canada License (including the non-exclusive license granted by Public Health Canada to NewLink under such Canada IP with respect to the Ebola (Sudan) Field of Use and the Ebola

[*]  Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 (Zaire) Gorilla Field of Use (as defined in the NewLink Canada License)). Without limiting the generality of the foregoing and notwithstanding anything to the contrary herein, Merck acknowledges and agrees that:

(a) the Field with respect to any Canada IP does not include any use or purpose for any animal disease, disorder or condition, with the exception of the Ebola (Zaire) Gorilla Field of Use (as defined in the NewLink Canada License);

(b) Public Health Canada’s prior written consent, not to be unreasonably withheld, is needed prior to Merck granting any sublicense to a Third Party of any Canada IP, other than a Merck Ordinary Course Sublicense (as defined in the NewLink Canada License); provided that a Merck Ordinary Course Sub-license (as defined in the NewLink Canada License) which would include a sub-sub-license of the majority of Merck’s Commercialization (as defined in the NewLink Canada License) rights to a Third Party shall also require such consent of Public Health Canada. At the request of Merck, NewLink shall seek any such consent from Public Health Canada; and

(c) the licenses granted to Merck hereunder (including any surviving licenses pursuant to Section 8.1) with respect to any Canada IP, if not earlier terminated, shall expire on July 28, 2033. Notwithstanding anything to the contrary contained herein, post expiration of the NewLink Canada License (i) Merck and its Related Parties shall thereafter be forever released from its confidentiality and non-use obligations with respect to Public Health Canada’s Confidential Information (as defined in the NewLink Canada License) and can use Public Health Canada’s Confidential Information (as defined in the NewLink Canada License) without obtaining permission from Public Health Canada or NewLink or making payment to Public Health Canada or NewLink and (ii) Public Health Canada can use its Confidential Information (as defined in the NewLink Canada License) as it sees fit, and, for the avoidance of doubt, this sentence shall survive any expiration or termination of this Agreement.
 
3.Capitalized terms used and not defined herein shall have the meaning ascribed to such terms in the Agreement. 

4.Except as specifically set forth in this Amendment, the Agreement will continue in full force and effect without change. If there is any conflict between the terms of this Amendment and the Agreement, this Amendment will govern.

5.This Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. In addition, this Amendment may be executed by facsimile or “PDF” and such facsimile or “PDF” signature shall be deemed to be an original.

6.This Amendment shall be governed by and construed in accordance with the laws of the State of New York and the patent laws of the United States without reference to any rules of conflict of laws or renvoi.    [Signature Page Follows]

[*]  Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

IN WITNESS WHEREOF, the Parties have executed this Amendment as of the Amendment Effective Date.

									
	Merck Sharp & Dohme Corp. 		Bioprotection Systems Corporation 
			
	By:  /s/ Benjamin Thorner 
		By:   /s/ Carl Langren

			
	Name:  Benjamin Thorner
		Name:  Carl Langren
			
	Title:  SVP & Head of BD&L
		Title:    Chief Financial Officer 
			
	Dated:  January 14, 2019 		Dated:  January 14, 2019Document

EXHIBIT  10.40.1

AMENDMENT NO. 1 TO THE AMENDED AND RESTATED LICENSE AGREEMENT FOR RECOMBINANT VESICULAR STOMATITIS VIRUS VACCINES FOR VIRAL HEMORRHAGIC FEVERS

between: 
HER MAJESTY THE QUEEN IN RIGHT OF CANADA, 
as represented by the Minister of Health, 
acting through the Public Health Agency of Canada 

(“Canada”)

AND: 
BIOPROTECTION SYSTEMS CORPORATION, 
a company incorporated as a subchapter C corporation 
under the laws of Delaware, having its registered office at 
Iowa State University Research Park, 
2901 South Loop Drive, Suite 3360, Ames, Iowa, USA 50010 

(“Company”)

WHEREAS Canada and the Company are party to that certain “Amended and Restated License Agreement for Recombinant Vesicular Stomatitis Virus Vaccines for Viral Hemorrhagic Fevers” dated December 5, 2017 (hereinafter the “License Agreement”); 
WHEREAS the Company has requested an amendment to the License Agreement to expand the Field of Use to include the Development and use of the Licensed Rights with injectable products in the field of prevention and prophylaxis against and treatment of Ebola (Zaire) in endangered gorilla populations in the Democratic Republic of the Congo (“DRC”), on a non-exclusive and royalty-free basis; 
AND WHEREAS Canada is willing to accept the Company’s request to amend the License Agreement for this specific purpose on the terms and conditions set out in this Amendment No.1 (hereinafter the “Amendment”) to the License Agreement. 
NOW THEREFORE, the Parties hereby agree as follows: 
 

1.Definitions.  Terms defined in this Amendment have the meanings assigned to them herein. Capitalized terms used in this Amendment without definition have the meanings assigned to them in the License Agreement.

2.Amendments.

a.The  License Agreement’s Introduction section is hereby amended to add the following after clause G. i) (b):

and (c) a non-exclusive, worldwide, revocable and royalty free license to make, use, improve and Develop  and Commercialize the technology in the field of prevention and prophylaxis against and treatment of Ebola (Zaire), a VHF virus, in endangered gorilla populations as identified by the Mountain Gorilla Veterinary Project (MGVP), whether before or after exposure; 

b.The definition of “Field of Use” in the License Agreement is hereby amended to add the following after clause 1.8 (ii):

; and (iii) the application and use of the Licensed Rights to injectable products to be sold or donated by the Company, or its Affiliates or sub-licensees, to the MGVP and the Gorilla Rehabilitation and Conservation Education Center (GRACE) Sanctuary for use in the field of prevention and prophylaxis against and treatment of Ebola (Zaire), a VHF virus, in gorillas which inhabit any of (a) the GRACE Sanctuary, (b) Senkwekwe Sanctuary, (c) Virunga National Park, or (d) Kahuzi Biega National Park, all within the Democratic Republic of the Congo (the “Ebola (Zaire) Gorilla Field of Use”), 

For greater certainty, the remainder of clause 1.8 that reads: “and for no other purposes whatsoever.” remains unchanged and in full effect. 

c.The License Agreement is hereby amended to add the following after clause 2.1 (b):

, and (c) a personal, non-exclusive, worldwide, revocable and royalty-free license for Development and Commercialization in the Ebola (Zaire) Gorilla Field of Use. 
For greater certainty, the remainder of clause 2.1 (b) remains unchanged and in full effect. 

3.The License Agreement is hereby amended to add the following after clause 5.2.3: 

5.2.4 For greater certainty, no amounts shall be owed to Canada under this paragraph 5.2 with respect to Sales of Licensed Products sold or donated by the Company, its Affiliates or sub-licensees to the MGVP and GRACE in the Ebola (Zaire) Gorilla Field of Use. 

4.Continuation of the License Agreement. Except for the amendments made in this Amendment, the License Agreement remains unchanged and in full effect.

5.Effective Date of Amendment. This Amendment shall come into force and effect on the date the last signature is affixed hereto by the duly authorized representatives of the Parties. 

IN WITNESS WHEREOF the Parties have executed this Amendment on the date(s) set out below by the hands of their duly authorized representatives. 
FOR HER MAJESTY THE QUEEN IN RIGHT OF CANADA: 

									
	/s/ Matthew W. Gilmour 		/s/ Dorothea Blandford 
			
	Signature 		Signature
			
	Scientific Director		Dorothea Blandford
	Name and Title 		Name of Witness 
			
	December 21, 2018		December 21, 2018
	Date 		Date
			
			

FOR BIOPROTECTION SYSTEMS CORPORATION: 

									
	/s/ Carl Langren 		/s/ Bradley Powers 
			
	Signature 		Signature
			
	Chief Financial Officer		Bradley Powers
	Name and Title 		Name of Witness 
			
	December 27, 2018		January 2, 2019
	Date 		Date
			
			

I have authority to bind the corporation

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00292-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00292-of-00352.parquet"}]]